8-K
filed August 1, 2023, 7:59 PM ET
ticker XTNT
CIK 0001453593
earnings
confidence high
sentiment positive
materiality 0.75
Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M
Xtant Medical Holdings, Inc.
2023-Q2 EPS reported
-$0.04
revenue$38,176,000
- Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).
- Gross margin 61.6%, up from 54.8% in Q2 2022, driven by Coflex/CoFix contribution.
- Net loss $2.2M ($0.02/share) vs $1.7M ($0.02) prior; adjusted EBITDA turned positive at $0.1M.
- Raises FY 2023 revenue guidance to $75-77M from $73-75M, representing 29-33% annual growth.
- CEO Sean Browne highlighted strength across channels and positive adjusted EBITDA ahead of expectations.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.
- Period
- second quarter ended June 30, 2023
- Net income
- -$2.2 million
- EPS
- -$0.02
- Result
- reported results
Exact text from the filing
Second quarter 2023 revenue grew 32%, representing organic growth of 14% plus an 18% increase from products added in the acquisition of the Coflex and CoFix lines, to $20.2 million, compared to $15.3 million for the same period in 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xtant Medical Holdings, Inc. reported second quarter ended June 30, 2023 results: net income -$2.2 million, EPS -$0.02.
- Period
- second quarter ended June 30, 2023
- Net income
- -$2.2 million
- EPS
- -$0.02
- Result
- reported results
Exact text from the filing
Second quarter 2023 net loss totaled $2.2 million, or $0.02 per share, compared to the second quarter 2022 net loss of $1.7 million, or $0.02 per share.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $75 million to $77 million. Guidance raised.
- Period
- full year 2023
- Revenue
- $75 million to $77 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company's prior guidance of $73 million to $75 million.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.